BGLC — Bionexus Gene Lab Income Statement
0.000.00%
- $9.12m
- $6.63m
- $9.77m
Annual income statement for Bionexus Gene Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.127 | 11.4 | 13.4 | 10.9 | 9.77 |
Cost of Revenue | |||||
Gross Profit | 0.056 | 1.72 | 2.27 | 1.26 | 1.33 |
Selling / General / Administrative Expenses | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.403 | 10.1 | 12.3 | 11.2 | 12.4 |
Operating Profit | -0.276 | 1.26 | 1.04 | -0.304 | -2.61 |
Net Income Before Taxes | -0.276 | 1.26 | 1.04 | -0.304 | -2.61 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.246 | 1.09 | 0.752 | -0.356 | -2.63 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.246 | 1.09 | 0.752 | -0.356 | -2.63 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.246 | 1.09 | 0.752 | -0.356 | -2.63 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.034 | 0.128 | 0.053 | -0.025 | -0.166 |
Dividends per Share |